The FDA has approved Xenleta (lefamulin; Nabriva Therapeutics) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
Represcription rate at 28 days only 4.1 percent from 2011 to 2015; slight increase seen for men over time
However, the results of a study titled Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis investigated whether a partial oral regimen may lead to equivalent outcomes.
The use of levofloxacin as prophylaxis for the prevention of neutropenic fever and bloodstream infections was associated with less disruption of the gut microbiome in patients with hematologic malignancy.
The FDA has approved pretomanid tablets in combination with bedaquiline and linezolid for the treatment of adults with pulmonary XDR, treatment-intolerant or nonresponsive MDR tuberculosis.
Investigators evaluated changes in the microbiology of osteomyelitis over a 10-year period, including infection with multidrug-resistant bacteria and susceptibility of antimicrobial regimens.
The researchers aimed to describe the incidence of bacteremia in patients with SLE, and identify risk factors.
The FDA has approved Sirturo (bedaquiline; Janssen) for use in pediatric patients aged 12 to less than 18 years for MDR-TB.
Investigators performed a comprehensive review on the prevalence of nonprescription antibiotic use in the United States and analyzed the factors that influence it.
Overuse of broad-spectrum antibiotics is associated with increased mortality and other poor outcomes in adults admitted for community-onset pneumonia.
